Cure Pharmaceutical Holding Corp.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2020 | $12 M | No. 2 | $10 to $50 million | debt, options | SEC | |
| May 2019 | $19 M | Issued in a merger or acquisition | $10 to $50 million | equity | SEC | |
| Mar 2018 | $1 M | No. 1 | Under $2 million | options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cure Pharmaceutical Holding Corp. chose not to state its revenue in its newest notice of a funding round (Nov 2020).
SEC Form D · Nov 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2020
That is all the official record says: Cure Pharmaceutical Holding Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Cure Pharmaceutical Holding Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 23 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Mike Redard | Executive officer | Nov 2020 |
| Robert Davidson | Executive officer | Nov 2020 |
| Alex Katz | Executive officer | May 2019 |
| Jessica Rousset | Executive officer | May 2019 |
| Mark Udell | Executive officer | May 2019 |
| Edward Maliski | Executive officer | Apr 2018 |
| Anya Goldin | Director | Nov 2020 |
| Gene Salkind | Director | Nov 2020 |
| John Bell | Director | Nov 2020 |
| Josh Held | Director | Nov 2020 |
| Lauren Chung | Director | Nov 2020 |
| Nancy Duitch | Director | Nov 2020 |
| Robert Davidson | Director | Nov 2020 |
| Ruben King-Shaw | Director | Nov 2020 |
| William Yuan | Director | Nov 2020 |
| Alan Einstein | Director | May 2019 |
| Charles Berman | Director | May 2019 |